Commentary: Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model

Frontiers in Microbiology

Volumn 7, Issue AUG, 2016, Pages

  Abedon, Stephen T ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Animal models; Antibacterial agents; Bacteriophages; Chronic infection; Phage therapy; Staphylococcal infections

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOFILM; BIOLOGICAL THERAPY; CHRONIC OSTEOMYELITIS; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOTE; PHAGE THERAPY; STAPHYLOCOCCAL CHRONIC OSTEOMYELITIS; TREATMENT RESPONSE;

EID: 84989172872     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.01251     Document Type: Note

References (20)

1. Abedon, S. T. (2011). Lysis from without. Bacteriophage 1, 46-49. doi: 10.4161/bact.1.1.13980
2. Capparelli, R., Nocerino, N., Iannaccone, M., Ercolini, D., Parlato, M., Chiara, M., et al. (2010). Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy. J. Infect. Dis. 201, 52-61. doi: 10.1086/648478
3. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., and Iannelli, D. (2007). Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 51, 2765-2773. doi: 10.1128/AAC.01513-06
4. Chhibber, S., Gupta, P., and Kaur, S. (2014). Bacteriophage as effective decolonising agent for elimination of MRSA from anterior nares of BALB/c mice. BMC Microbiol. 14:212. doi: 10.1186/s12866-014-0212-8
5. Chibani-Chennoufi, S., Sidoti, J., Bruttin, A., Kutter, E., Sarker, S., and Brüssow, H. (2004). In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob. Agents Chemother. 48, 2558-2569. doi: 10.1128/AAC.48.7.2558-2569.2004
6. Danelishvili, L., Young, L. S., and Bermudez, L. E. (2006). In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. Microb. Drug Res. 12, 1-6. doi: 10.1089/mdr.2006.12.1
7. Drilling, A., Morales, S., Boase, S., Jervis-Bardy, J., James, C., Jardeleza, C., et al. (2014). Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis. Int. Forum Allergy Rhinol. 4, 176-186. doi: 10.1002/alr.21270
8. Kishor, C., Mishra, R. R., Saraf, S. K., Kumar, M., Srivastav, A. K., and Nath, G. (2016). Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J. Med. Res. 143, 87-94. doi: 10.4103/0971-5916.178615
9. Langdon, A., Crook, N., and Dantas, G. (2016). The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 8:1. doi: 10.1186/s13073-016-0294-z
10. Mendes, J. J., Leandro, C., Corte-Real, S., Barbosa, R., Cavaco-Silva, P., Melo-Cristino, J., et al. (2013). Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen. 21, 595-603. doi: 10.1111/wrr.12056
11. Miedzybrodzki, R., Borysowski, J., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., et al. (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121. doi: 10.1016/B978-0-12-394438-2.00003-7
12. Olsen, I. (2015). Biofilm-specific antibiotic tolerance and resistance. Eur. J. Clin. Microbiol. Infect. Dis. 34, 877-886. doi: 10.1007/s10096-015-2323-z
13. Payne, R. J. H., and Jansen, V. A. A. (2001). Understanding bacteriophage therapy as a density-dependent kinetic process. J. Theor. Biol. 208, 37-48. doi: 10.1006/jtbi.2000.2198
14. Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., and Sulakvelidze, A. (2009). Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18, 237-244. doi: 10.12968/jowc.2009.18.6.42801
15. Shivaswamy, V. C., Kalasuramath, S. B., Sadanand, C. K., Basavaraju, A. K., Ginnavaram, V., Bille, S., et al. (2015). Ability of bacteriophage in resolving wound infection caused by multidrug-resistant Acinetobacter baumannii in uncontrolled diabetic rats. Microb. Drug Resist. 21, 171-177. doi: 10.1089/mdr.2014.0120
16. Singla, S., Harjai, K., Katare, O. P., and Chhibber, S. (2015). Bacteriophage-loaded nanostructured lipid carrier: improved pharmacokinetics mediates effective resolution of Klebsiella pneumoniae induced lobar pneumonia. J. Infect. Dis. 212, 325-334. doi: 10.1093/infdis/jiv029
17. Tanji, Y., Shimada, T., Fukudomi, H., Miyanaga, K., Nakai, Y., and Unno, H. (2005). Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J. Biosci. Bioeng. 100, 280-287. doi: 10.1263/jbb.100.280
18. Trigo, G., Martins, T. G., Fraga, A. G., Longatto-Filho, A., Castro, A. G., Azeredo, J., et al. (2013). Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl. Trop. Dis. 7:e2183. doi: 10.1371/journal.pntd.0002183
19. Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., et al. (2007). Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51, 446-452. doi: 10.1128/AAC.00635-06
20. Wright, A., Hawkins, C. H., Anggård, E. E., and Harper, D. R. (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryng. 34, 349-357. doi: 10.1111/j.1749-4486.2009.01973.x